chidamide + rituximab

Chidamide + rituximab is a combination therapy regimen being investigated for the treatment of diffuse large B-cell lymphoma (DLBCL), particularly in high-risk populations such as elderly patients with MYC/BCL2 double-expressor subtypes. Chidamide (also known as tucidinostat) is a benzamide-based selective histone deacetylase (HDAC) inhibitor that targets HDAC1, HDAC2, HDAC3, and HDAC10. By inhibiting these enzymes, chidamide induces epigenetic modifications that lead to cell cycle arrest and apoptosis in malignant B-cells. Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B-lymphocytes. It mediates cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. The combination is often studied as a maintenance therapy following induction with regimens like R-mini CHOP to improve progression-free survival by simultaneously targeting epigenetic regulation and surface markers.

Other names

chidamide plus rituximabchidamide and rituximabchidamide plus CD20 monoclonal antibody